EUCTR2011-002891-18-IT进行中（未招募）不适用
Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. - IRST 100.06
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst2-positive (breast, small cell lung cancer, Hodgkin and Non-Hodgkin lymphoma, high-grade glioma etc…….), that may benefit from receptor radionuclide therapy and for which there aren’t any other effective treatments. Any disease stage is allowed. Patient could be enrolled with progressive disease (PD within the last 12 months from treatment start) but also with non progressive disease. Patients with documented disease will be admitted to therapeutic phase only if the diagnostic OctreoScan and/or PET/CT 68Ga-peptide images demonstrate a significant uptake in the tumour.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •- pazienti già trattati con 177Lu-dotatate o 90Y-dotatoc, a dosi cumulative superiori a 600 mCi e 200 mCi rispettivamente - pazienti trattati con CT e RT da meno di 4 settimane - pazienti con gravi comorbidità
研究者
相似试验
进行中（未招募）
不适用
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line - IRST162.02oncological patientsMedDRA version: 12.1Level: LLTClassification code 10026532Term: Malignant neoplasm of thoraxEUCTR2010-018333-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. - NDcancer patientsMedDRA version: 9.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2007-005517-20-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
1 期
Therapy with radiopharmaceutical 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in patients with diagnosis of somatostatin receptor positive tumor: a multicenter, prospective phase 2 studyPatients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positiveMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2023-000086-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS268
招募中
1 期
Radioimmunotherapy with 177Lu-DOTA-RITUXIMAB in B-cell lymphomaIRCT20210612051548N4Boushehr University of Medical Sciences10
尚未招募
2 期
Endoradiotherapy with 177Lu-Trastuzumab in patients with HER2-positive breast cancerMalignant breast cancer.Malignant neoplasm of breastIRCT20210612051548N3Boushehr University of Medical Sciences15